- Home
- ALT vs CGEM Comparison
ALT vs CGEM Comparison
Compare ALT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- CGEM
- Stock Information
- Founded
- ALT 1997
- CGEM 2016
- Country
- ALT United States
- CGEM United States
- Employees
- ALT N/A
- CGEM N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ALT Health Care
- CGEM Health Care
- Exchange
- ALT Nasdaq
- CGEM Nasdaq
- Market Cap
- ALT 472.3M
- CGEM 506.1M
- IPO Year
- ALT N/A
- CGEM 2021
- Fundamental
- Price
- ALT $5.32
- CGEM $8.02
- Analyst Decision
- ALT Strong Buy
- CGEM Strong Buy
- Analyst Count
- ALT 8
- CGEM 8
- Target Price
- ALT $21.00
- CGEM $32.86
- AVG Volume (30 Days)
- ALT 3.0M
- CGEM 416.8K
- Earning Date
- ALT 05-08-2025
- CGEM 05-14-2025
- Dividend Yield
- ALT N/A
- CGEM N/A
- EPS Growth
- ALT N/A
- CGEM N/A
- EPS
- ALT N/A
- CGEM N/A
- Revenue
- ALT $20,000.00
- CGEM N/A
- Revenue This Year
- ALT N/A
- CGEM N/A
- Revenue Next Year
- ALT N/A
- CGEM $278.37
- P/E Ratio
- ALT N/A
- CGEM N/A
- Revenue Growth
- ALT N/A
- CGEM N/A
- 52 Week Low
- ALT $5.14
- CGEM $7.90
- 52 Week High
- ALT $11.16
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- ALT 39.42
- CGEM 36.91
- Support Level
- ALT $5.60
- CGEM $8.01
- Resistance Level
- ALT $6.16
- CGEM $9.16
- Average True Range (ATR)
- ALT 0.35
- CGEM 0.48
- MACD
- ALT 0.01
- CGEM -0.00
- Stochastic Oscillator
- ALT 17.65
- CGEM 4.90
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.